Daesang stock reports 8.3 percent Q2 revenue growth

Published on 10/07/2026 at 01:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Daesang stock was last at KRW 17,550 on October 6, 2026, down 1.57 percent on KOSPI. Two analysts rate it Outperform with an average target of KRW 32,500.

Daesang, KR7001680008, Illustration mit AI erstellt.

Daesang stock (ISIN KR7001680008) was last at KRW 17,550 on the Korea Exchange KOSPI on October 6, 2026 at 3:30 p.m. KST, down 1.57 percent from the prior close. The company reported Q2 2026 revenue of KRW 1.17 trillion, giving the shares a fundamental checkpoint after a weaker trading session.

Revenue reaches KRW 1.17 trillion

According to ATS View, Daesang generated Q2 revenue of KRW 1.17 trillion, up 8.3 percent year over year. Operating profit reached KRW 46.5 billion, equal to a 4.0 percent operating margin, while net income was KRW 19.6 billion.

The quarter shows a mixed earnings profile. Revenue increased from KRW 1.11 trillion in Q1 2026, but operating profit declined from KRW 57.0 billion and net income fell from KRW 32.6 billion, according to ATS View. For investors, the comparison places more weight on margin conversion than on sales growth alone.

Analysts see a higher valuation

Daesang was last at KRW 17,550 on October 6, 2026, with a market capitalization of KRW 608.1 billion and trading volume of 75,052 shares. The stock sits between its 52-week low of KRW 15,880 and high of KRW 24,150, leaving the latest price 27.5 percent above the low and 27.3 percent below the high.

According to MarketScreener, two analysts give Daesang an Outperform consensus and an average target of KRW 32,500. The target lies 85.2 percent above the October 6 price, although the small analyst sample makes the consensus narrower than coverage of larger Korean food companies.

Amino acids add a second growth path

MarketScreener reported on September 9, 2026 that Daesang is expanding into high-purity pharmaceutical-grade amino acids. The initiative builds on the acquisition of Germany-based AMINO GmbH and adds medical infusion, clinical nutrition and biopharmaceutical applications to Daesang's existing food and materials businesses.

The operating figures explain why this strategy matters. Q2 revenue growth reached 8.3 percent, but the 4.0 percent operating margin remained below the 5.1 percent reported for Q1, making profitability the key financial measure for the next update.

Daesang stock stays below its yearly high

Daesang stock was last at KRW 17,550 on October 6, 2026 at 3:30 p.m. KST. The KRW 608.1 billion market capitalization and the 1.57 percent daily decline put the latest trading signal alongside the company's improving revenue but lower sequential profit.